Evidence map›Paper›PMID 27037688›Full record

Observational studyJournal of endocrinological investigation2016

Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.

G Rastrelli, L Giovannini, A E Calogero, D Gianfrilli, E Serra, A Pizzocaro, V A Giagulli, G Motta, G Vancieri, A Sperandio and 6 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of endocrinological investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Isolated hypoprolactinemia: The rarest of the rare?Reviews in endocrine & metabolic disorders · 2024
    Review
  5. Review
  6. Article
  7. Testosterone deficiency in non-cancer opioid-treated patients.Journal of endocrinological investigation · 2018
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

G RastrelliSexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy.
L GiovanniniEndocrinology Unit, Department of Clinical and Molecular Sciences, Umberto I Hospital, Polytechnic University of Marche, Ancona, Italy.
A E CalogeroDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
D GianfrilliDepartment of Experimental Medicine, La Sapienza University of Rome, Rome, Italy.
E SerraDepartment of Internal Medical Sciences, Endocrinology and Metabolic Diseases Unit, Cagliari, Italy.
A PizzocaroEndocrinology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
V A GiagulliOutpatient Clinic for Endocrinology and Metabolic Diseases, Conversano Hospital, Conversano, Bari, Italy.
G MottaDepartment of Medical Sciences, Division of Endocrinology, Diabetology and Metabolism, University of Turin, Turin, Italy.
G VancieriSection of Reproductive Endocrinology and Andrology, Hospital San Giovanni Calibita Fatebenefratelli Isola Tiberina, University of Rome TorVergata, Rome, Italy.
A SperandioAndrology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
S AndòDepartment of Pharmacy, Health and Nutrition Sciences, University of Calabria, Rende, Italy.
R SeliceDepartment of Molecular Medicine, Section of Clinical Pathology and Center for Human Reproduction Pathology, University of Padova, Via Gabelli 63, 35121, Padua, Italy.
G LucaDepartment of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy.
F CocchiaraDepartment of Endocrinological and Medical Sciences, University of Genova, Genoa, Italy.
D CanaleEndocrine Unit, University of Pisa Medical School and Hospitals, Ospedale di Cisanello, Pisa, Italy.
M MaggiSexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. mario.maggi@unifi.it.
University of Florence · ITIRCCS Humanitas Research Hospital · ITMarche Polytechnic University · ITSapienza University of Rome · ITUniversity of Cagliari · ITUniversity of Calabria · ITUniversity of Catania · ITUniversity of Genoa · ITUniversity of L'Aquila · ITUniversity of Padua · ITUniversity of Perugia · ITUniversity of Pisa · ITUniversity of Rome Tor Vergata · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeManagement of late onset hypogonadism (LOH) is not homogenous. The aim of the study is to observe the management of patients with low testosterone (T) in highly specialized Italian centres.

methodsThe SIAMO-NOI is an observational longitudinal disease registry for the evaluation of the clinical management of patients with low T levels (total T < 12 nmol/L, calculated free T < 225 pmol/l or already in treatment) in 15 Italian centers members of the Italian Society for Andrology and Sexual Medicine (SIAMS). Clinical and biochemical data were collected for four visits during 12 months of observation.

results432 patients (mean age 50.9 ± 14.9 years) were enrolled. Of them, 247 men were receiving androgen therapy, whereas 145 were naive. After the first visit (V0), 80 men started androgen therapy, whereas 55 remained untreated during the entire observation. Younger age [odds ratio (OR) 0.57 (0.35-0.92)], total T < 8 nmol/l [OR 4.69 (1.59-13.81)], complaining at least one sexual symptom [OR 11.55 (2.01-66.35)] and reporting more severe lower urinary tract symptoms [OR 1.27 (1.01-1.60)] predicted starting an androgen therapy. Sixty-four men started therapy immediately after V0 and maintained it until the observation end. When compared to V0, they reported an increase in all the domains of the International Index of Erectile Function-15 (IIEF-15), in the sexual and physical subdomains of the Aging Male Scale as well as in the International Prostate Symptom Score. Conversely, the untreated group reported a significant improvement, although lower than the treated group, only in the erectile function domain of the IIEF-15.

conclusionsManagement of LOH in SIAMS centres is in line with the international guidelines and the newest knowledge about the role of T on prostate health. Androgen therapy is associated with an improvement in all the aspects of sexual life and in the perception of physical strength.

Indexed as

AndrogensErectile DysfunctionHormone Replacement TherapyHumansHypogonadismLongitudinal StudiesMaleMiddle AgedRegistriesSurveys and QuestionnairesTestosteroneAndrogensTestosteroneAndrogen therapyLate onset hypogonadismLower urinary tract symptomsPredictorsSexual symptomsTestosterone

Identifiers

PMID27037688
OpenAlexW2319053950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.